Market Report: AstraZeneca strengthen with purchase of asthma drug
Thursday 31 July 2014
AstraZeneca is trying to make good on its promise to investors that it’s better off alone.
The pharmaceutical giant rebuffed Pfizer’s £55 a share takeover offer two months ago, setting out a strategy for going it alone that many saw as over ambitious. Yesterday boss Pascal Soriot shrugged off doubts, strengthening the company’s pipeline with the $2.1bn (£1.2bn) purchase of an asthma drug developed by Spanish outfit Almirall.
There are rumours of another deal: Astra is said to be sniffing about German biotech outfit Evotec, with Johnson & Johnson also thought to be interested. Astra climbed 35p to 4,357.5p.
The blue-chip FTSE 100 index was once again on the back foot, retreating 34.31 points to 6,773.44. Most put the slump down to fears over Russia’s reaction to sanctions from the US and EU. Even better than expected US GDP numbers arriving in the afternoon failed to ease the gloom.
Results drove much of the day’s trading activity. Better than expected half-year figures from Barclays, up 9.3p to 228.4p, sparked a resurgence for banks, and lenders added 3.99 points to the index.
Despite rising copper production in the second quarter and steady full-year forecasts, Chilean miner Antofagasta slipped 39p to 816p, as falling metal prices led to rising costs.
Rio Tinto slipped 41p to 3,434p, after offloading assets in Mozambique at a huge loss: it paid $3.7bn for Riversdale Mining in 2011 but yesterday revealed it had sold on the company’s coking coal operations for just $50m.
Pets at Home shot up 12p to 182p on the mid-cap index after a solid set of results, while accessory specialist 4imprint leapt up 60.5p to 705p after what Espirito Santo Bank dubbed a “stunning” set of first half numbers.
AIM-listed Summit Corporation climbed 4.5p to 108p as chief executive Glyn Edwards spent £31,000 on shares. African iron and manganese producer Ferrex lost 0.32p to 1.1p – its project in Gabon has fallen through. Technology company Tern jumped 0.5p to 2.12p, as director Al Sisto advanced £100,000 to the company prior to converting it into new equity.
- 1 Hair loss explained: How and why men go bald
- 2 Game of Thrones season 6: Jon Snow theorists believe the Stark may have a twin sister
- 3 Artist takes LSD, draws herself over different stages of the 9-hour trip to show its effects
- 4 A pint of water every day is the key to losing weight, scientists say
- 5 Russia 'accidentally reveals' number of its soldiers killed in eastern Ukraine
Most expensive city to live in for expatriates: Luanda, Angola takes number one spot with Hong Kong and Zurich in top three
Video of Irish 'professional boxer' fighting Istanbul neighbourhood goes viral in Turkey
Irish tourist filmed fighting with shopkeepers in Turkey says they 'messed with the wrong man'
House of Lords: Outcry as donors, fixers and MPs caught up in expenses scandal get peerages
Moody neurotics are more likely to be creative geniuses, study says
Dresden riots: Protesters in Germany attack refugee buses shouting 'foreigners out'
France train shooting: US soldiers speak of the moment they stopped gunman and 'beat him until he was unconscious'
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith calls for urgent ESA overhaul as part of drive to cut down welfare costs
iJobs Money & Business
£13000 - £25000 per annum: Recruitment Genius: Would you like to be part of a ...
£20000 - £25000 per annum + competitive: SThree: Are you passionate about sale...
£25000 per annum + benefits: Ashdown Group: A large financial services company...
£20400 per annum: Ashdown Group: An established and highly reputable organisat...